Onderneming NuGenerex Immuno-Oncology, Inc.
Aandelen
NUGX
US67053X1028
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 6
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Moscato
CEO | Chief Executive Officer | 61 | 01-01-17 |
Mark Corrao
DFI | Director of Finance/CFO | 67 | - |
Eric von Hofe
PSD | President | 66 | - |
Jason Terrell
CTO | Chief Tech/Sci/R&D Officer | 43 | - |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 18-01-17 |
Director/Board Member | 54 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marvin Hausman
BRD | Director/Board Member | 82 | - |
Brian T. McGee
BRD | Director/Board Member | 63 | - |
Carol A. Nacy
BRD | Director/Board Member | 76 | - |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 18-01-17 |
Craig Eagle
BRD | Director/Board Member | 57 | - |
Joseph Moscato
CEO | Chief Executive Officer | 61 | 01-01-17 |
Director/Board Member | 54 | - | |
Thomas Leonard
BRD | Director/Board Member | 50 | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 101 196 670 | 33 149 554 ( 32,76 %) | 0 | 32,76 % |
Bedrijfsgegevens
NuGenerex Immuno-Oncology, Inc.
10102 USA Today Way Suite 200
33025, Miramar
+(416) 364-2551
http://www.nugenerexio.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |